

Breast cancer: Neoadjuvant chemotherapy and ovarian function suppression update

Advisory Committee Interests Register

Register last updated: 10/04/2025

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Adam Firth	Chair	Direct financial	GP Partner, Bracondale Medical Centre, Stockport	Jul 2013	May 2022	Ongoing	Declare and participate. Rationale: Salaried employment in NHS.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct financial	Clinical Academic Consultant, University of Southampton	2009	Dec 2022	Ongoing	Declare and participate. Rationale: Salaried employment as clinical academic.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial professional and personal and direct financial	Honorary position at University of Southampton for clinical work at University Hospital Southampton. This occasionally involves taking on additional work extra to contract (which is paid) on an ad-hoc basis.	2009	Dec 2022	Ongoing	Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect, financial Direct, non-financial,	Head of Academic Clinical Training at Wessex Deanery, Health Education England. Unpaid position but University of Southampton and University Hospital Southampton	Oct 2022	Dec 2022	Ongoing	Declare and participate.

		professional and personal	receive funding to release my time for the secondment.				Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Trustee and Chair of Academic and Research Committee, of the Charity Association of Breast Surgery.	2019	Jul 2022	May 2024	Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Breast Surgery Subspecialty Editor of the Journal Annals of the Royal College of Surgeons.	2015	Jul 2022	Ongoing	Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Member of Grant Review Committee of the Charity Breast Cancer Now.	2019	Jul 2022	Ongoing	Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Member of the Scientific Advisory Board of the Charity Against Breast Cancer.	2021	Jul 2022	Ongoing	Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Member of independent trial steering committee of the POSNOC trial (of adjuvant therapy alone v adjuvant therapy plus clearance for women with metastases in 1 or 2 sentinel nodes). Secondary	2014	Jul 2022	Ongoing	Declare and participate. Rationale: interest is non-specific.

			endpoints include arm morbidity and lymphoedema.				
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Member of the UK Breast Cancer Clinical Studies Group (Breast Research Group).	2017	Jul 2022	Ongoing	Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect, financial Direct, non-financial, professional and personal	Grant from Astra-Zeneca to the University of Southampton to fund long-term follow-up of the study: ‘Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study’ . RC is a co-applicant.	Nov 2021	Jul 2022	Ongoing	Declare and participate. Rationale: interest is not specific to the topics covered in this update.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect, financial Direct, non-financial, professional and personal	SECA have provided equipment for the measurement of body composition to the University Hospital Southampton as part of a model industry collaborative agreement. This equipment is being used in a clinical study to measure body composition in patients with breast cancer for which RC is CI.	2013	Jul 2022	Ongoing	Declare and participate. Rationale: interest is non-specific..
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect, financial Direct, non-financial,	Lead investigator of the EndoNET trial of Neoadjuvant endocrine therapy and linked translational study TransEndoNET	2021	Aug 2023	Ongoing	Declare and participate. Rationale: interest is not specific to this update as

		professional and personal					neoadjuvant endocrine therapy is out of scope.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect, financial Direct, non-financial, professional and personal	Chief Investigator of the CANDO3 trial of body composition and chemotherapy toxicity in breast cancer	2018	Aug 2023	Ongoing	Declare and participate. Rationale: interest is not specific to the topics covered in this update.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect, financial Direct, non-financial, professional and personal	Vice Chair of UK Breast Cancer Clinical Studies Group genomic working group and prior to that Member of their Breast Clinical Studies Group. The NCRI announced its closure in July 23 and is now known as the UK Breast Cancer Clinical Studies Group.	2017	Aug 2023		Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct financial	As Association of Breast Surgery Academic and Research Committee Chair involvement in discussion with Astra Zeneca around development of a possible Royal College of Surgeons of England Clinical Research Fellowship in breast surgery. If this proceeds it is envisaged that the fellowship would be administered and run,	2019	Feb 2024	May 2024	Declare and participate. Rationale: interest is non-specific.

			and appointed through open competition and peer review, by the RCS England according to their established processes.				
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect financial Direct, non-financial, professional and personal	Academic investigator led (non-commercial) research with Ramsey Cutress as Lead or Co applicant is supported by research grants from the National Institute for Health Research (NIHR) and research and hospital charities (Breast Cancer Now, Prevent Breast Cancer, Cancer Research UK and Southampton Hospitals Charity).		Sep 2024		Declare and participate. Rationale: interest is non-specific.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect financial Direct, non-financial, professional and personal	Academic grant from the charity Prevent Breast Cancer: Risk prediction for young-onset breast cancer and involvement of tumour-infiltrating lymphocytes. Grant Reference ID: GA23-05. Prevent breast cancer Co-I, £39,871.20.	2022	Sep 2024		Declare and participate. Rationale: interest is not specific to the topics covered in this update
Ramsey Cutress	Topic Adviser – Breast Surgeon	Indirect financial Direct, non-financial, professional and personal	Academic grant from the charity Cancer Research UK: Cancer Research UK CRUK Southampton Clinical Academic Training Programme. Ref:	2024	Sep 2024		Declare and participate. Rationale: interest is non-specific.

			SEBCATP-2024/100002Co-Applicant.				
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Co-author: Fatayer H, O'Connell RL, Bannon F, Coles CE, Copson E, Cutress RI, Dave RV, Gardiner MD, Grayson M, Holcombe C, Irshad S, Irwin GW, O'Brien C, Palmieri C, Shaaban AM, Sharma N, Singh JK, Whitehead I, Potter S, McIntosh SA; NeST Study Research Collaborative. Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study. Br J Surg. 2022 Aug 16;109(9):800-803. doi: 10.1093/bjs/znac131. Erratum in: Br J Surg. 2022 Dec 13;110(1):124. doi: 10.1093/bjs/znac282. PMID: 35543289; PMCID: PMC10364769.	Dec 2022	Feb 2025		Declare and participate Rationale: Interest is specific, but study not included in evidence base as looks at current practice in UK rather than comparing types of NA chemotherapy. Open declaration is sufficient mitigation.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Co-author: Whitehead I, Irwin GW, Bannon F, Coles CE, Copson E, Cutress RI, Dave RV, Gardiner MD, Grayson M, Holcombe C, Irshad S, O'Brien C, O'Connell RL, Palmieri C, Shaaban AM, Sharma N, Singh JK, Potter S, McIntosh SA; NeST Study Research Collaborative. The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United	Jan 2021	Feb 2025		Declare and participate Rationale: Interest is specific, but study not included in evidence base as looks at current practice in UK rather than comparing types of NA chemotherapy. Open

			Kingdom multi-disciplinary decision making. BMC Cancer. 2021 Jan 22;21(1):90. doi: 10.1186/s12885-020-07757-6. PMID: 33482770; PMCID: PMC7825231.				declaration is sufficient mitigation.
Ramsey Cutress	Topic Adviser – Breast Surgeon	Direct, non-financial, professional and personal	Co-author: Irwin GW, Bannon F, Coles CE, Copson E, Cutress RI, Dave RV, Grayson M, Holcombe C, Irshad S, O'Brien C, O'Connell RL, Palmieri C, Shaaban AM, Sharma N, Singh J, Whitehead I, Potter S, McIntosh SA. The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer. Int J Surg Protoc. 2019 Nov 11;18:5-11. doi: 10.1016/j.isjp.2019.10.002. PMID: 31897446; PMCID: PMC6921204.	Nov 2019	Feb 2025		Declare and participate Rationale: Interest is specific, but study not included in evidence base as looks at current practice in UK rather than comparing types of NA chemotherapy. Open declaration is sufficient mitigation.
Kwok Leung Cheung	Committee member – Breast Surgeon	Direct financial	Professor of Breast Surgery and Medical Education, University of Nottingham (substantive employer)		Dec 2022	Ongoing	Declare and participate. Rationale: Salaried employment as clinical academic.

Kwok Leung Cheung	Committee member – Breast Surgeon	Direct, non-financial professional and personal	Honorary Consultant Breast Surgeon, University Hospitals of Derby and Burton NHS Foundation Trust (honorary employer)		Dec 2022		Declare and participate. Rationale: Honorary employment in NHS.
Kwok Leung Cheung	Committee member – Breast Surgeon	Direct financial	Private clinical practice in Breast Surgery at Derby Private Health. Private practice accounts for <5% of overall practice.	2001	Jul 2022	Ongoing	Declare and participate. Rationale: private practice is limited.
Kwok Leung Cheung	Committee member – Breast Surgeon	Direct, non-financial professional and personal	External professional Advisor to the Parliamentary and Health Service Ombudsman for Breast surgery and breast cancer.	2008	Jul 2022	Ongoing	Declare and participate. Rationale: open declaration is sufficient mitigation.
Kwok Leung Cheung	Committee member – Breast Surgeon	Direct, non-financial professional and personal	UK National Representative, International Society of Geriatric Oncology (SIOG)	2013	Jul 2022	ongoing	Declare and participate. Rationale: interest is non-specific.
Kwok Leung Cheung	Committee member – Breast Surgeon	Direct, non-financial professional and personal	Member, SIOG Public Policy Ad-hoc Committee	Oct 2021	Jul 2022	Ongoing	Declare and participate. Rationale: interest is non-specific.
Kwok Leung Cheung	Committee member –	Direct, non-financial	Member, Surgical Speciality Board in General Surgery (sub-speciality	Jul 2022	Jul 2022	Ongoing	Declare and participate.

	Breast Surgeon	professional and personal	breast surgery), Royal College of Surgeons Edinburgh				Rationale: interest is non-specific.
Kwok Leung Cheung	Committee member – Breast Surgeon	Direct, non-financial professional and personal	President-Elect, International Society of Geriatric Oncology (SIOG). Term ends Nov 2026.	Nov 2024	Mar 2025		Declare and participate. Rationale: interest is non-specific.
Kayleigh Davies-Crowley	Committee member – Advanced Nurse Practitioner	Direct financial	Breast Advanced Nurse Practitioner, Royal Liverpool Hospital		Sep 2024		Declare and participate. Rationale: Salaried employment in the NHS.
Mark Davies	Committee member – Medical Oncologist	Direct financial	Consultant in Medical Genetics, Swansea Bay University Health Board		Aug 2023		Declare and participate. Rationale: Salaried employment in the NHS.
Mark Davies	Committee member – Medical Oncologist	Direct financial	A member of the Advisory Board - Stemline Therapeutics. Advise on developing ESR1 testing. ESR1 is a genetic biomarker that guides use of the drug elacestrant.	Jun 2023	Aug 2023	Aug 2023	Declare and participate. Rationale: interest is not specific to the topics covered in this update.
Mark Davies	Committee member –	Direct financial	Member of the Advisory Board-Roche. Advise on the use of mass	Jul 2023	Aug 2023	Ongoing	Declare and participate.

	Medical Oncologist		spectrometry to guide endocrine therapy in breast cancer.				Rationale: interest is not specific to this update as the use of mass spectrometry to guide endocrine therapy in breast cancer is out of scope.
Mark Davies	Committee member – Medical Oncologist	Direct financial	Payment for Novartis speaking engagement, talk at UK Oncology Masterclass on Hot Topics in Genetics	Jun 2023	Aug 2023	Jun 2023	Declare and participate. Rationale: interest is non-specific.
Mark Davies	Committee member – Medical Oncologist	Direct, non-financial, professional and personal	Honorary Professor, Swansea University	Jun 2021	Aug 2023	Ongoing	Declare and participate. Rationale: Honorary employment as clinical academic.
Mark Davies	Committee member – Medical Oncologist	Direct, non-financial, professional and personal	Deputy Chair, All Wales Genomics Oncology Group	Jun 2021	Aug 2023	Ongoing	Declare and participate. Rationale: interest is non-specific.
Mark Davies	Committee member – Medical Oncologist	Direct, non-financial, professional and personal	Co-author on paper 'A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX	Jun 2022	Aug 2023	Jun 2022	Declare and participate. Rationale: interest is non-specific to this update as adjuvant

			® testing to guide adjuvant chemotherapy decisions.’				chemotherapy is out of scope.
Mark Davies	Committee member – Medical Oncologist	Direct, non-financial, professional and personal	Local sub investigator on OPTIMA study. This study aims to evaluate a gene assay to guide chemotherapy decisions in high-risk breast cancer	Jun 2017	Aug 2023	Ongoing	Declare and participate. Rationale: interest is not specific to the topics covered in this update.
Mark Davies	Committee member – Medical Oncologist	Direct, non-financial, professional and personal	Local principal investigator - Partner trial	Jan 2019	Aug 2023	Ongoing	Declare and participate. Rationale: interest is non-specific to this update as the drug being trialled is out of scope of this update.
Mark Davies	Committee member – Medical Oncologist	Direct, non-financial, professional and personal	Local principal investigator - Destiny 09 trial	Mar 2022	Aug 2023	Ongoing	Declare and participate. Rationale: interest is non-specific to this update as the drug being trialled and the population of interest is out of scope of this guideline.

Mark Davies	Committee member – Medical Oncologist	Direct, non-financial, professional and personal	Local principal investigator - Nerlyfe study	Feb 2022	Aug 2023	Ongoing	Declare and participate. Rationale: interest is non-specific to this update as adverse events of extended adjuvant treatment is out of scope.
Mark Davies	Committee member – Medical Oncologist	Direct-financial	Travel expense paid by Fields Institute in Toronto to attend workshop on mathematical oncology	Sep 2024	Sep 2024	Sep 2024	Declare and participate. Rationale: interest is non-specific.
Milly Finch	Committee member - Pharmacist	Direct financial	Consultant oncology pharmacist at Calderdale And Huddersfield Foundation NHS Trust		Jun 2024	Ongoing	Declare and participate. Rationale: Salaried employment in NHS.
Milly Finch	Committee member - Pharmacist	Direct financial	Seagen- provided an educational lecture series	Jul 2023	Aug 2023	Oct 2023	Declare and participate. Rationale: interest is non-specific.
Milly Finch	Committee member - Pharmacist	Indirect	Husband works for Pharmaxo	Jul 2023	Aug 2023	Ongoing	Declare and participate. Rationale: Indirect

Milly Finch	Committee member - Pharmacist	Direct financial	Celltrion- paid sponsorship to attend BOPA 2023 symposium	Oct 2023	Nov 23	Oct 2023	Declare and participate. Rationale: interest is non-specific.
Milly Finch	Committee member - Pharmacist	Direct financial	Royal Pharmaceutical Society- Consultant pharmacist portfolio board member; reviewing portfolios	Nov 2023	Nov 23	ongoing	Declare and participate. Rationale: interest is non-specific.
Milly Finch	Committee member - Pharmacist	Direct financial	Pfizer sponsored attendance and accommodation at the BOPA 2024 symposium.	Oct 2024	Nov 2024	Oct 2024	Declare and participate. Rationale: interest is non-specific.
Milly Finch	Committee member - Pharmacist	Direct, non-financial, professional and personal	Chief investigator on real world data collection on Olaparib in early breast cancer	Aug 2024	Feb 2025	Ongoing	Declare and participate. Rationale: interest is non-specific to this update as the drug concerned is out of scope.
Rachael Griffin	Committee member - Lay member	Indirect	RG's company Jazz Pharmaceuticals are in clinical trials developing a drug called Zanidatamab for HER2 positive cancers including breast. RG is not working on this drug as supports healthy volunteer clinical trials.	Sep 2024	Sep 2024	ongoing	Declare and participate. Rationale: Indirect

Sadaf Haque	Committee member – General Practitioner	Direct financial	Salaried General Practitioner, Rosebank Health Primary Care Network, Gloucester	2017	Mar 2023	ongoing	Declare and participate. Rationale: Salaried employment in NHS.
Sadaf Haque	Committee member – General Practitioner	Direct financial	Clinical Lead Cancer, NHS Gloucestershire	2013	Mar 2023	Ongoing	Declare and participate. Rationale: Salaried employment in NHS.
Sadaf Haque	Committee member – General Practitioner	Direct financial	Breast Physician, Gloucestershire Hospitals NHS Foundation Trust	2022	Mar 2023	Ongoing	Declare and participate. Rationale: Salaried employment in NHS.
Sadaf Haque	Committee member – General Practitioner	Direct financial	Chair Gloucestershire GP Education Trust - this is a membership charitable organisation offering aspirational GP education with local provider colleagues and as Education Programme Director and Honorary Tutor SH takes an active role in forming policy/ strategy and planning/ facilitating educational events. SH kite-marks all GGPET education sessions for quality of GP education. SH attends NHS Gloucestershire's monthly HEE Training Hub meetings.	2013	Mar 2023	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Tim Robinson	Committee member - Medical Oncologist	Direct financial	Consultant Senior Lecturer and Honorary Consultant Oncologist, University of Bristol		10/2023	Ongoing	Declare and participate. Rationale: Salaried employment as clinical academic.
Tim Robinson	Committee member - Medical Oncologist	Direct financial	Private practice in breast medical oncology. Private practice makes up approx. 10% of overall practice and mirrors NHS practice.	Dec 2022	Oct 2023	Ongoing	Declare and participate. Rationale: private practice is limited.
Tim Robinson	Committee member - Medical Oncologist	Direct, non-financial, professional and personal	General educational talks for Breast Cancer Now to patient groups around topics of breast cancer - such as triple negative breast cancer or managing metastatic disease	Jun 22	Oct 2023	Ongoing	Declare and participate. Rationale: Interest is specific but talks were general open declaration is sufficient mitigation.
Tim Robinson	Committee member - Medical Oncologist	Direct financial	Chief Investigator of a clinical trial. Trial is sponsored by MedSIR and funded by Debiopharm a Swiss pharmaceutical company. Some drug for the study is also being provided free of charge by Gilead. Study will investigate a novel drug produced by debiopharm (Debio-0123) compared with a drug from Gilead that is standard of care. TR will receive a small financial benefit from functioning as chief	Sep 2023	Oct 2023	Ongoing	Non-specific Declare and participate, Rationale: Open declaration is sufficient mitigation

			investigator of the study but not contingent on the results. This will come from MedSIR the sponsor. There will also be institutional funding for research work and a clinical PhD student.				
Tim Robinson	Committee member - Medical Oncologist	Direct, non-financial, professional and personal	Working on a trial proposal examining the use of digital tools in survivorship care with Novartis.	Sep 2023	Oct 2023	Apr 2024	Declare and participate. Rationale: Interest is non-specific.
Tim Robinson	Committee member - Medical Oncologist	Direct financial	Travel and accommodation to attend San Antonio Breast Cancer Symposium funded by MSD.	Dec 2023	Nov 2023	Dec 2023	Declare and participate. Rationale: Interest is non-specific.
Tim Robinson	Committee member - Medical Oncologist	Direct financial	Travel and accommodation to attend ESMO 2024 congress funded by Novartis.	Sep 2024	Aug 2024	Sep 2024	Declare and participate. Rationale: Interest is non-specific.
Tim Robinson	Committee member - Medical Oncologist	Direct financial	Paid to give a talk on Breast Cancer Treatment Pathway to non-medical prescribers for an evening event in Sept 24 by Novartis.	Sep 2024	Aug 2024	Sep 2024	Declare and participate. Rationale: Interest is non-specific.
Tim Robinson	Committee member -	Direct, non-financial,	Is on an ESMO Breast Poster with Novartis looking at cost of		Feb 2025		Declare and participate.

	Medical Oncologist	professional and personal	recurrence of early-stage breast cancer				Rationale: Interest is non-specific.
Tim Robinson	Committee member - Medical Oncologist	Indirect financial	Novartis sponsored local breast cancer unit meeting in Bristol in March 2025. Novartis have no input into the content of this day, only supporting rental of a room and some food. They will be doing a promotional talk at the break.	Mar 2025	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Direct financial	Professor of Molecular Breast Cancer Genetics and Honorary Consultant in Clinical Oncology, Kings College London		Mar 2024	Ongoing	Declare and participate. Rationale: Salaried employment as clinical academic.
Elinor Sawyer	Committee member – Clinical Oncologist	Direct financial	Currently undertakes private practice at the private HCA facility in the Cancer Centre at Guy's and St Thomas' Hospital and at the London Radiotherapy Centre. Approx. 10% of practice is private and private practice mirrors NHS practice.	2009	Feb 2024	Ongoing	Declare and participate. Rationale: private practice is limited.
Elinor Sawyer	Committee member – Clinical Oncologist	Direct, non-financial, professional and personal	I am on the scientific advisory board of the patient advocacy group: Lobular Breast Cancer UK	2022	Feb 2024	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Elinor Sawyer	Committee member – Clinical Oncologist	Indirect, Financial Direct, Non-financial, professional and personal	Current research awards listed below and are all paid to KCL and fund research staff and consumables. They do not fund EL salary and EL receives no direct funding. CANCER RESEARCH UK – PRECISION GRAND CHALLENGE 1/5/2017 – 30/4/2027	May 2017	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Indirect, Financial Direct, Non-financial, professional and personal	CANCER RESEARCH UK – SAMBAI GRAND CHALLENGE 1/5/2024 – 30/4/2029	May 2024	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Indirect, Financial Direct, Non-financial, professional and personal	CANCER RESEARCH UK – Does the microenvironment influence relapse after breast radiotherapy 1/11/2023-31/10/2026	Nov 2023	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Indirect, Financial Direct, Non-financial, professional and personal	BREAST CANCER NOW- Influence of the tumour microenvironment in invasive lobular carcinoma of the Breast, Principal 1/5/2024-30/4/2025	May 2024	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Indirect, Financial Direct, Non-financial,	US Department of Defense Clinical Trial extension award (IMPROVE DCIS) 1/10/2023-30/9/2027	Oct 2023	Feb 2025		Declare and participate.

		professional and personal					Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Indirect, Financial	Kings Health Partners Breast Cancer Real World Evidence Programme received £ 79,300 from IQVIA to provide data for a collaborative research project. This funding was paid to Guys and St Thomas Hospitals Trust and is being used to cover the salary of the database manager	Dec 2024	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Indirect, Financial	Kings Health Partners Breast Cancer Real World Evidence Programme received £50,000 from OXON epidemiology to provide data for a collaborative research project. This funding was paid to Guys and St Thomas Hospitals Trust and is being used to cover the salary of the database manager	Jan 2025	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
Elinor Sawyer	Committee member – Clinical Oncologist	Direct, non-financial, professional and personal	Joint lead of the Clinical Working Group for the European Lobular Consortium	2024	Feb 2025		Declare and participate. Rationale: Interest is non-specific.
David Talbot	Committee member – Lay Member		None declared				N/A

Katy Tan	Committee member - Lay member	Direct financial	Employment – Reckitt (a hygiene, health and nutrition company).	Jan 2009	Aug 2023	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Katy Tan	Committee member - Lay member	Direct financial	Shareholder – Indivior (pharmaceutical company for addiction and serious mental illness).		Aug 2023	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Katy Tan	Committee member - Lay member	Direct financial	Shareholder – Reckitt (a hygiene, health and nutrition company).		Aug 2023	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Ben Thwaites	Committee member - Pharmacist	Direct financial	Employment as Lead Pharmacist Oncology (Sutton), The Royal Marsden NHS Foundation Trust	Mar 2023	Nov 2023	Ongoing	Declare and participate. Rationale: Salaried employment in NHS.
Ben Thwaites	Committee member - Pharmacist	Direct financial	Novartis – sponsorship for attendance at the BOPA Symposium 2023, including travel and accommodation	Oct 2023	Nov 2023	Oct 2023	Declare and participate. Rationale: Interest is non-specific.
Ben Thwaites	Committee member - Pharmacist	Direct financial	Support offered by Roche to attend the British Oncology Pharmacy Association symposium between the 11th and 13th October 2024.	Oct 2024	Aug 2024	Oct 2024	Declare and participate. Rationale: Interest is non-specific.

			Registration, travel and accommodation covered.				
--	--	--	---	--	--	--	--

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.